IP Library Granted Patent US 11,730,711
Granted Patent B2
US 11,730,711 · App. 17/175,111 · Granted Aug 22, 2023

Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels

Inventors: Stephen Kirnon (San Ramon, CA); Eric Freedland (Marblehead, MA); Rajagopal V. Sekhar (Missouri City, TX)
Assignees: Baylor College of Medicine; Societe de Produits Nestle S.A.
A61K31/198A23K20/142A23K50/50A61K31/167A61K31/205A61K31/223A61K31/27A61K31/341A61K31/381A61K31/683A61K38/02A61K38/05A61K38/21A61K45/06A61P21/00A61P29/00A61P31/18A61P39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,711
App. No.
17/175,111
Granted
Aug 22, 2023
Kind
B2
Abstract

Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

Claims (19)

1. A method of treating an individual for a medical condition or physical state, the method comprising providing to the individual an effective amount of a composition comprising glycine or a functional derivative thereof and N-acetylcysteine, wherein the medical condition or physical state is selected from the group consisting of:

muscle loss;

deleterious effects of weightlessness;

osteoporosis;

polycystic ovary syndrome (PCOS);

coronary artery disease;

myocardial damage after stress;

insufficient immunity following vaccination;

ototoxicity;

dizziness; and

a combination thereof.

2. The method of claim 1 , wherein the glycine or functional derivative thereof and the N-acetylcysteine are provided to the individual in the same composition.

3. The method of claim 1 , wherein the glycine or functional derivative thereof and the N-acetylcysteine are provided to the individual in different compositions.

4. The method of claim 1 , wherein the glycine or functional derivative thereof and the N-acetylcysteine are provided orally to the individual.

5. The method of claim 1 , wherein the functional derivative of glycine is selected from the group consisting of D-Allylglycine; N-[Bis(methylthio)methylene]glycine methyl ester; Boc-allyl-Gly-OH (dicyclohexylammonium) salt; Boc-D-Chg-OH; Boc-Chg-OH; (R)—N-Boc-(2′-chlorophenyl)glycine; Boc-L-cyclopropylglycine; (R)—N-Boc-4-fluorophenylglycine; Boc-D-propargylglycine; Boc-(S)-3-thienylglycine; Boc-(R)-3-thienylglycine; D-α-Cyclohexylglycine; L-α-Cyclopropylglycine; N-(2-fluorophenyl)-N-(methyl sulfonyl) glycine; N-(4-fluorophenyl)-N-(methyl sulfonyl)glycine; Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH; N-(2-Furoyl)glycine; L-α-Neopentylglycine; D-Propargylglycine; sarcosine; Z-α-Phosphonoglycine trimethyl ester; and a mixture thereof.

6. The method of claim 1 , wherein the glycine and the N-acetylcysteine are comprised in a dipeptide.

7. The method of claim 6 , wherein the dipeptide comprises N-acetylcysteinylglycine or cysteinylglycine.

8. The method of claim 1 , wherein the medical condition or physical state comprises muscle loss.

9. A method of achieving an effect in an individual, selected from the group consisting of cancer prevention; fetal metabolic programming for prevention of later development of obesity and/or diabetes; prophylaxis for nephropathy; and prevention for acetaminophen toxicity, the method comprising providing to the individual an effective amount of a composition comprising a functional derivative of glycine and further comprising N-acetylcysteine.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2023
From: PHARMAPLAN LLC
To: VITAVIS LABORATORIES, INC.
Reel/Frame 063034/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2023
From: VITAVIS LABORATORIES, INC.
To: NESTEC S.A.
Reel/Frame 063034/0541 →
MERGER Recorded Mar 20, 2023
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 063034/0586 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2023
From: KIRNON, STEPHEN; FREEDLAND, ERIC; SEKHAR, RAJAGOPAL V.
To: BAYLOR COLLEGE OF MEDICINE; PHARMAPLAN LLC
Reel/Frame 063119/0723 →
Continuity (3)
Continuation 15577422
Provisional Application 62167433 · May 28, 2015
Related Publication 20210244696A1 · Aug 12, 2021
Cited By (1)
US 12,186,292